Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion ...

The pharma giant struck a licensing deal to gain access to delivery technologies developed by U.S. startup Vivtex., to deepen ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures ...

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% ...

Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for ...

The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the ...

The healthcare company said all doses will shift to a single monthly list price, cutting Wegovy’s price by about 50% and ...

Click in for more news from The Hill {beacon} Health Care   The Big Story Novo Nordisk plans to slash GLP-1 prices The list ...

Novo Nordisk’s post-trial sell-off may be overdone. Click here for this comparative analysis of NVO and LLY stocks and see ...

Novo Nordisk is repriced as if its fundamentals have sharply deteriorated, despite strong underlying demand. Learn why NVO stock is rated a buy.

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

It would be a near-miracle gain.